New Zealand markets open in 9 hours 25 minutes

BIIB Jan 2024 170.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
9.290.00 (0.00%)
As of 03:43PM EST. Market open.
Full screen
Previous close9.29
Expiry date2024-01-19
Day's range9.29 - 9.29
Contract rangeN/A
Open interestN/A
  • Motley Fool

    Can These 2 Stocks Crush the Market Again in 2023?

    The list includes Regeneron Pharmaceuticals (NASDAQ: REGN) and Biogen (NASDAQ: BIIB). Regeneron was having an unimpressive year on the stock market until its shares soared by double-digit percentages in one day in September. As is often the case with biotechs, Regeneron owes this move to positive clinical developments.

  • Motley Fool

    Is Biogen Stock a Buy Now?

    Thanks to well-received clinical trial data for its investigational Alzheimer's therapy, lecanemab, shares of Biogen (NASDAQ: BIIB) are up by more than 51% in the past three months -- and the company hasn't even made a single dollar from the positive findings yet. Including lecanemab, Biogen has a dozen programs in late-stage clinical trials, all but four of which are being developed for indications in neurology. Its areas of focus within neurology are Alzheimer's disease and Parkinson's disease, though it also has a trio of programs for multiple sclerosis (MS) in development.

  • Motley Fool

    Is Anavex Life Sciences a Smart Stock to Buy Now?

    Shares of clinical-stage biotechnology company Anavex Life Sciences (NASDAQ: AVXL) recently shot higher. Investors reacting to great news for its Alzheimer's disease drug candidate, blarcamesine, drove the stock about 40% higher when the market opened on Friday, Dec. 2. Is Anavex Life Sciences a smart stock to buy now, or will the road ahead be a rocky one full of potholes?